Literature DB >> 11971716

Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants.

David A Becker1, James J Ley, Luis Echegoyen, Robert Alvarado.   

Abstract

Stilbazulenyl nitrone (STAZN), 8, a nitronyl-substituted hydrocarbon, is a novel second-generation azulenyl nitrone with significantly enhanced potency as a chain-breaking antioxidant vs conventional alpha-phenyl nitrones previously investigated as antioxidant therapeutics. A convenient (1)H NMR-based assay for assessing the potency of chain-breaking antioxidants has shown that STAZN is ca. 300 times more potent in inhibiting the free radical-mediated aerobic peroxidation of cumene than is PBN and the experimental stroke drug NXY-059. Such levels of antioxidant efficacy are unprecedented among archetypal alpha-phenyl nitrone spin traps. Furthermore, STAZN outperforms such classical phenolic antioxidants as BHT and probucol and rivals the antioxidant potency of Vitamin E in a polar medium comprised of 80% cumene and 20% methanol. The Volodarskii electron-transfer mechanism involving the intermediacy of the STAZN radical cation has been implicated in attempts to ascertain the basis for the increased potency of STAZN over the three alpha-phenyl nitrones PBN, S-PBN, and NXY-059.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971716     DOI: 10.1021/ja011507s

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  20 in total

1.  De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays.

Authors:  Paul A Lapchak; David R Schubert; Pamela A Maher
Journal:  Transl Stroke Res       Date:  2011-06       Impact factor: 6.829

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

3.  Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2011-06-01       Impact factor: 6.829

Review 4.  Antioxidant pharmacological therapies for COPD.

Authors:  Irfan Rahman; William MacNee
Journal:  Curr Opin Pharmacol       Date:  2012-02-18       Impact factor: 5.547

Review 5.  Pharmacological antioxidant strategies as therapeutic interventions for COPD.

Authors:  Irfan Rahman
Journal:  Biochim Biophys Acta       Date:  2011-11-09

6.  Dimethyl cis-2-methyl-3-p-tolyl-isoxazolidine-4,5-dicarboxyl-ate.

Authors:  Mustafa Odabaşoğlu; Hamdi Ozkan; Yılmaz Yıldırır; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-03-19

7.  Reactivity of superoxide radical anion with cyclic nitrones: role of intramolecular H-bond and electrostatic effects.

Authors:  Frederick A Villamena; Shijing Xia; John K Merle; Robert Lauricella; Beatrice Tuccio; Christopher M Hadad; Jay L Zweier
Journal:  J Am Chem Soc       Date:  2007-06-12       Impact factor: 15.419

8.  Neuroprotective effect of STAZN, a novel azulenyl nitrone antioxidant, in focal cerebral ischemia in rats: dose-response and therapeutic window.

Authors:  James J Ley; Ludmila Belayev; Isabel Saul; David A Becker; Myron D Ginsberg
Journal:  Brain Res       Date:  2007-05-26       Impact factor: 3.252

Review 9.  Antioxidant therapeutic advances in COPD.

Authors:  Irfan Rahman
Journal:  Ther Adv Respir Dis       Date:  2008-12       Impact factor: 4.031

10.  Neuroprotective antioxidant STAZN protects against myocardial ischemia/reperfusion injury.

Authors:  James J Ley; Ricardo Prado; Jian Qin Wei; Nanette H Bishopric; David A Becker; Myron D Ginsberg
Journal:  Biochem Pharmacol       Date:  2007-09-08       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.